BACKGROUND
For 120 years now, Santen has been continuing its commitment to improving the eyesight and health of patients across the globe, building upon a spirit of creation, innovation and strong company values.
Santen SAS has been marketing the company’s ophthalmological products in France since 2014. The French company is also a Santen Group Center of Excellence dedicated to innovative ophthalmological R&D for all eye segments.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
Santen SAS has a sales and marketing organization to commercialize pharmaceutical ophthalmic products in France.
In terms of research activities, within Santen we have concentrated our basic research, non-clinical studies, and drug formulation research at Nara R&D Center, so as to integrate the knowledge of our various sections and create better products. In 2011, Santen purchased Novagali Pharma (today Santen S.A.S.), a French ophthalmic pharmaceutical company that has excellent R&D capability and drug formulation technologies in the dry eye field. This purchase has reinforced Santen’s development pipelines, enhancing its international competitiveness in the ophthalmic field.
